Based on our previous findings that TAGLN inhibition can enhance the functionality of GDM-ECFCs15,30, we designed a nanocarrier system to deliver small molecule SB-431542 (TGF-β inhibitor) for sustained pseudo-autocrine stimulation to therapeutic cells (Fig. 1a). Here, TGFB1 is linked to gestational diabetes.